Status:
WITHDRAWN
MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imaging
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Cancéropôle GSO and GIRCI SOOM (API-K)
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This feasibility exploratory study objective is to assess the ability of combined MRI BOLD and 18F-MISO PET imaging to visualize tumor hypoxia compare to histological results obtained after radical pr...
Detailed Description
Prostate cancer is the fisrt one in male with 80.000 new cases each year in France. Forty thousand curative treatments are performed each year, but 25 to 30% of these patients will present a cancer re...
Eligibility Criteria
Inclusion
- Patient above 18.
- Prostate tumor with histological confirmed diagnosis and highly radiological suspected target on MRI
- High risk patient : \>T2c grade, Glasgow score \> 7 and PSA \> 20ng/ml
- Surgical treatment chosen during multidisciplinary meeting
- ECOG ≤2
- Patient must have undergone MRI with BOLD sequence less than 6 month prior surgery
- Member or beneficiary of a social security system.
- Signed informed consent.
Exclusion
- Patient included in another clinical study
- Geographical, social or psychological reasons preventing patient from submitting to the study's medical monitoring
- Patient deprive of liberty, adult subjects to legal protection or unable to give consent
- Contraindications to MRI
- Contraindication to gadolinium injection
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03293602
Start Date
September 1 2019
End Date
January 1 2020
Last Update
November 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Lutte Contre le Cancer
Toulouse, France, 31300